Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Определено ли место β-адреноблокаторов при лечении артериальной гипертонии? - Журнал Системные Гипертензии №2 (2006)
Определено ли место β-адреноблокаторов при лечении артериальной гипертонии?
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. The HDFP cooperative group. Persistence of reduction in blood pressure and mortality of participantesin the Hypertension Detection and Folloiw-up Program. JAMA 1988; 259: 2113–22.
2. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise chouse? Lancet 2004; 364: 1684–9.
3. Lindholm LH, Carlberg B, Samuelsson O. Shoud β−blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
4. Beevers DG. The end of β-blockers for uncomplicated hypertension? Ibid: 1510–2.
5. Wikstrand J, Warnold I, Olsson G et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259 (13): 1976–82.
6. Wikstrand J. Primary prevention in patients with hypertension: Comments on the clinical implications of the MAPHY Study. Am Heart Journal July 1988; 116: 338–46.
7. Wikstrand J, Warnold I, Tuomilehto J et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991; 17: 579–88.
8. Wilhelmsen L, Berglund G, Elmfeldt D et al. Beta-Blockers Versus Diuretics in Hypertensive Men: Main Results from the HAPPHY Trial. Journal of Hypertension 1987; 5: 561–72.
9. Maphy and the Two Arms of Happhy. JAMA 1989; 262 (23): 3272-4.
10. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Применение суперселективного бета-адреноблокатора небиволола у пациентов с сердечно-сосудистой патологией в сочетании с бронхообструктивным синдромом. Рос. кардиол. журн. 2006; 2 (58): 78–82.
11. Matthys H, Giebelhaus V, Von Fallois J. Nebivolol (nebilet) a beta-blocker of the third generation – also for patients with obstructive lung diseases? Z Kardiol 2001; 90 (10): 760–5.
12. Maffei A, Vecchione C, Aretini A et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19 (6): 579–86.
13. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1: 2–16.
14. Dessy C, Saliez J, Ghisdal P et al. Endothelial beta-3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112 (8): 1198–205.
15. Garban HJ, Buga GM, Ignarro LJ. Estrogen-receptor mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 2004; 43 (5): 638–44.
16. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747–52.
17. Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49 (2): 430–9.
18. Von Fallois J, Faulhaber HD. Nebivolol, a beta-blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study. Schweiz Rundsch Med Prax 2001; 90 (11): 435–41.
19. Глезер М.Г., Бойко Н.В., Абильдинова А.Ж., Соболев К.Э. Сравнительная эффективность лечения небивололом и бисопрололом больных артериальной гипертензией. Кардиоваск. тер. и проф. 2004; 3 (5): 43–50.
20. Brett SE, Forte P, Chowienczyk PJ et al. Comparison of the effects of nebivolol and bisoprolol on systematic vascular resistance in patients with essential hypertension. Clin Drug Invest 2002; 22 (6): 355–9.
21. Бувальцев В.И., Спасская М.Б., Небиеридзе Д.В. и др. Фармакологическая модуляция синтеза NO у пациентов с артериальной гипертензией и эндотелиальной дисфункцией. Клин. мед. 2003; 81 (7): 51–5.
22. Fratta Passini A, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23 (3): 589–96.
23. Kaplan NM, Opie LH. Controversies in Cardiology 2. Controversies in hypertension. Lancet 2006; 367: 168–76.
24. New BHS-NICE guidelines (June 2006). Prescription guidelines in cardiology. Editions Frison-Roche. 2006.
25. Expert consensus document on β-adrenergic receptor blockers. The task Force on Beta-Blockers of the European Society of Cardiology. Europ Heart J 2004; 25 (15): 1341–62.
2. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise chouse? Lancet 2004; 364: 1684–9.
3. Lindholm LH, Carlberg B, Samuelsson O. Shoud β−blockers first chouse in the treatment of primary hypertension? A meta-analisys. Lancet 2005; 366: 1545–53.
4. Beevers DG. The end of β-blockers for uncomplicated hypertension? Ibid: 1510–2.
5. Wikstrand J, Warnold I, Olsson G et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259 (13): 1976–82.
6. Wikstrand J. Primary prevention in patients with hypertension: Comments on the clinical implications of the MAPHY Study. Am Heart Journal July 1988; 116: 338–46.
7. Wikstrand J, Warnold I, Tuomilehto J et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991; 17: 579–88.
8. Wilhelmsen L, Berglund G, Elmfeldt D et al. Beta-Blockers Versus Diuretics in Hypertensive Men: Main Results from the HAPPHY Trial. Journal of Hypertension 1987; 5: 561–72.
9. Maphy and the Two Arms of Happhy. JAMA 1989; 262 (23): 3272-4.
10. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Применение суперселективного бета-адреноблокатора небиволола у пациентов с сердечно-сосудистой патологией в сочетании с бронхообструктивным синдромом. Рос. кардиол. журн. 2006; 2 (58): 78–82.
11. Matthys H, Giebelhaus V, Von Fallois J. Nebivolol (nebilet) a beta-blocker of the third generation – also for patients with obstructive lung diseases? Z Kardiol 2001; 90 (10): 760–5.
12. Maffei A, Vecchione C, Aretini A et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19 (6): 579–86.
13. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1: 2–16.
14. Dessy C, Saliez J, Ghisdal P et al. Endothelial beta-3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112 (8): 1198–205.
15. Garban HJ, Buga GM, Ignarro LJ. Estrogen-receptor mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 2004; 43 (5): 638–44.
16. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747–52.
17. Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49 (2): 430–9.
18. Von Fallois J, Faulhaber HD. Nebivolol, a beta-blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study. Schweiz Rundsch Med Prax 2001; 90 (11): 435–41.
19. Глезер М.Г., Бойко Н.В., Абильдинова А.Ж., Соболев К.Э. Сравнительная эффективность лечения небивололом и бисопрололом больных артериальной гипертензией. Кардиоваск. тер. и проф. 2004; 3 (5): 43–50.
20. Brett SE, Forte P, Chowienczyk PJ et al. Comparison of the effects of nebivolol and bisoprolol on systematic vascular resistance in patients with essential hypertension. Clin Drug Invest 2002; 22 (6): 355–9.
21. Бувальцев В.И., Спасская М.Б., Небиеридзе Д.В. и др. Фармакологическая модуляция синтеза NO у пациентов с артериальной гипертензией и эндотелиальной дисфункцией. Клин. мед. 2003; 81 (7): 51–5.
22. Fratta Passini A, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23 (3): 589–96.
23. Kaplan NM, Opie LH. Controversies in Cardiology 2. Controversies in hypertension. Lancet 2006; 367: 168–76.
24. New BHS-NICE guidelines (June 2006). Prescription guidelines in cardiology. Editions Frison-Roche. 2006.
25. Expert consensus document on β-adrenergic receptor blockers. The task Force on Beta-Blockers of the European Society of Cardiology. Europ Heart J 2004; 25 (15): 1341–62.
Авторы
В.И.Маколкин
Московская медицинская академия им. И.М.Сеченова
Московская медицинская академия им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.